Article
Acquired genetic and cell-state changes in IDH-mutant glioma progression.
Nature - 1 Jul 2026
Johnson Kevin C, Spitzer Avishay, Varn Frederick S, Nomura Masashi, Garofano Luciano, Chowdhury Tamrin, Lipsa Anuja, Zhang Linbin, Fernández Ester Calvo, Barak Tanyeri, Gulhan Ercan-Sencicek A, Peksen Ayse Buket, Anderson Kevin J, Tesileanu C Mircea S, Amin Samirkumar B, Kocakavuk Emre, Zhao Dacheng, D'Angelo Fulvio, Migliozzi Simona, Bussema Lillian, Gritsch Simon, Moon Hyo-Eun, Paek Sun Ha, Bielle Franck, Laurenge Alice, Di Stefano Anna Luisa, Mathon Bertrand, Picca Alberto, Sanson Marc, Hau Ann-Christin, Hertel Frank, Grzyb Kamil, Zhao Zheng, Wang Qianghu, Jiang Tao, Miller Julie J, Wakimoto Hiroaki, Cahill Daniel P, Moliterno Jennifer, Günel Murat, Hermes Beth, Sanai Nader, Golebiewska Anna, Niclou Simone P, Huse Jason, Alfred Yung W K, Lasorella Anna, Suvà Mario L, Iavarone Antonio, Tirosh Itay, Verhaak Roel G W
Abstract excerpt
Gliomas with mutant isocitrate dehydrogenase (IDH) are malignant brain tumours that typically arise in early to mid-adulthood and nearly always recur following treatment1,2. However, the genetic and cellular-state changes that drive IDH-mutant glioma progression under treatment remain incompletely understood. Here we integrated single-nucleus transcriptomic profiles, chromatin accessibility profiles and bulk DNA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.